The relationship between inflammatory and oxidative stress biomarkers, atherosclerosis and rheumatic diseases

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 585-600

  Şerban, Corina ^a   Drǎgan, Simona ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Atherosclerosis; Biomarkers; Cardiovascular risk; Circulating biomarkers; Inflammation; Oxidative stress; Rheumatic diseases; Screening

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATHEPSIN S; CD40 LIGAND; ENDOTHELIN 1; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 33; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PENTRAXIN 3; PHOSPHOLIPASE A2; SERUM AMYLOID A; SERUM AMYLOID P; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; ENDOTHELIAL PROGENITOR CELL; HUMAN; INFLAMMATION; METABOLOMICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATION MEDIATORS; MASS SCREENING; OXIDATIVE STRESS; PROGNOSIS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84894054801     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282004140213145806     Document Type: Article

References (239)

1. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123: 551-65.
2. Vivanco F, Padial LR, Darde VM, et al. Proteomic Biomarkers of Atherosclerosis. Biomark Insights 2008; 3: 101-113.
3. Gasparyan AY. Inflammation, thrombosis and vascular biology: translating ideas into cardiovascular research and therapy. Open Cardiovasc Med J 2010; 4: 20-2.
4. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 969-79.
5. Alvarez-Llamas G, de la Cuesta F, Barderas ME, Darde V, Padial LR, Vivanco F. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective. Expert Rev Proteomics 2008; 5: 679-91.
6. Hermus L, Lefrandt JD, Tio RA, Breek JC, Zeebregts CJ. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010; 213: 21-9.
7. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-62.
8. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-93.
9. Romanens M, Ackermann F, Spence JD, et al. Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. Eur J Cardiovasc Prev Rehabil 2010; 17: 18-23.
10. Kampoli AM, Tousoulis D, Antoniades C, Siasos G, Stefanadis C. Biomarkers of premature atherosclerosis. Trends Mol Med 2009; 15: 323-32.
11. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
12. Balagopal PB, de Ferranti SD, Cook S, et al. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation 2011; 123: 2749-69.
13. Abbasi SH, Boroumand MA. Expanded network of inflammatory markers of atherogenesis: where are we now? Open Cardiovasc Med J 2010; 4: 38-44.
14. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
15. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
16. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
17. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
18. Yan RT, Fernandes V, Yan AT, et al. Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2010; 160: 479-86.
19. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, Creactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007; 50: 1115-22.
20. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-9.
21. Bello G, Cailotto F, Hanriot D, et al. C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis 2008; 200: 286-93.
22. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.
23. Kawanami D, Maemura K, Takeda N, et al. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis 2006; 185: 39-46.
24. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.
25. Danesh J, Pepys MB. C-reactive protein and coronary disease: is there a causal link? Circulation 2009; 120: 2036-9.
26. Danesh J, Erqou S, Walker M, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007; 22: 839-69.
27. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-40.
28. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 2005; 180: 189-95.
29. Liu HH, Zhao D, Ma CS, et al. C-reactive protein predicts the severity of coronary artery disease beyond low-density lipoprotein cholesterol. Angiology 2012; 63: 218-22.
30. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-40.
31. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005; 109: 171-6.
32. Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012; 32: 287-94.
33. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519-30.
34. Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007; 34: 964-8.
35. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-21.
36. Takahashi H. [High-sensitivity C-reactive protein (CRP) assay-a novel method for assessment of risk ratios for atherosclerotic vascular diseases]. Rinsho Byori 2002; 50: 30-9.
37. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in Creactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.
38. McMurray JJ, Kjekshus J, Gullestad L, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120: 2188-96.
39. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009; 25: 567-79.
40. Kozan O, Buyukozturk K, Ilerigelen B, Kabakci G, Koylan N. The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients: results of the ICEBERG study. J Clin Hypertens (Greenwich) 2007; 9: 500-5.
41. Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008; 29: 499-508.
42. Ridker PM. High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque: more evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction. Circ Cardiovasc Imaging 2011; 4: 195-7.
43. Rezaieyazdi Z, Sahebari M, Hatef MR, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus 2011; 20: 1494-500.
44. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a nonredundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21 Suppl 2: S43-7.
45. Garlanda C, Bottazzi B, Moalli F, et al. Pentraxins and atherosclerosis: the role of PTX3. Curr Pharm Des 2011; 17: 38-46.
46. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994; 84: 3483-93.
47. Doni A, Peri G, Chieppa M, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003; 33: 2886-93.
48. Camozzi M, Zacchigna S, Rusnati M, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005; 25: 1837-42.
49. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010; 20: 35-40.
50. Rusnati M, Camozzi M, Moroni E, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-9.
51. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-41.
52. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-54.
53. Matsui S, Ishii J, Kitagawa F, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010; 210: 220-5.
54. Hollan I, Bottazzi B, Cuccovillo I, et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010; 62: 378-85.
55. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011; 22: 302-7.
56. Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012; 19: 5-14.
57. Witting PK, Song C, Hsu K, et al. The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med 2011; 51: 1390-8.
58. Marhaug G, Harklau L, Olsen B, Husby G, Husebekk A, Wang H. Serum amyloid A protein in acute myocardial infarction. Acta Med Scand 1986; 220: 303-6.
59. Tolle M, Huang T, Schuchardt M, et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of proinflammatory-serum amyloid A. Cardiovasc Res 2012; 94: 154-62.
60. Migita K, Koga T, Satomura K, et al. Serum amyloid A triggers the mosodium urate-mediated mature interleukin-1beta production from human synovial fibroblasts. Arthritis Res Ther 2012; 14: R119.
61. Connolly M, Mullan RH, McCormick J, et al. Acute-phase serum amyloid A regulates tumor necrosis factor alpha and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum 2012; 64: 1035-45.
62. Emsley J, White HE, O'Hara BP, et al. Structure of pentameric human serum amyloid P component. Nature 1994; 367: 338-45.
63. Li XA, Hatanaka K, Ishibashi-Ueda H, Yutani C, Yamamoto A. Characterization of serum amyloid P component from human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 252-7.
64. Li XA, Yutani C, Shimokado K. Serum amyloid P component associates with high density lipoprotein as well as very low density lipoprotein but not with low density lipoprotein. Biochem Biophys Res Commun 1998; 244: 249-52.
65. Song Z, Cai L, Guo L, Tsukamoto Y, Yutani C, Li XA. Accumulation and expression of serum amyloid P component in human atherosclerotic lesions. Atherosclerosis 2010; 211: 90-5.
66. Stewart CR, Haw A, 3rd, Lopez R, et al. Serum amyloid P colocalizes with apolipoproteins in human atheroma: functional implications. J Lipid Res 2007; 48: 2162-71.
67. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2007; 27: 352-8.
68. Bijl M, Bootsma H, Van Der Geld Y, et al. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004; 63: 831-5.
69. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
70. Ivey ME, Osman N, Little PJ. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008; 199: 237-47.
71. Kedzierski RM, Yanagisawa M. Endothelin system: the doubleedged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-76.
72. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007; 5: 45-52.
73. Cesari M, Pavan E, Sacchetto A, Rossi GP. Endothelin-1: a scientist's curiosity, or a real player in ischemic heart disease? Am Heart J 1996; 132: 1236-43.
74. Tykocki NR, Watts SW. The interdependence of endothelin-1 and calcium: a review. Clin Sci (Lond) 2010; 119: 361-72.
75. Browatzki M, Schmidt J, Kubler W, Kranzhofer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 2000; 95: 98-105.
76. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000; 269: 713-7.
77. Fan J, Unoki H, Iwasa S, Watanabe T. Role of endothelin-1 in atherosclerosis. Ann N Y Acad Sci 2000; 902: 84-93; discussion 93-4.
78. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14: 83S-89S.
79. Kanaya AM, Barrett-Connor E, Wassel Fyr CL. Endothelin-1 and prevalent coronary heart disease in older men and women (the Rancho Bernardo Study). Am J Cardiol 2007; 99: 486-90.
80. Perez del Villar C, Garcia Alonso CJ, Feldstein CA, Juncos LA, Romero JC. Role of endothelin in the pathogenesis of hypertension. Mayo Clin Proc 2005; 80: 84-96.
81. Pinto-Sietsma SJ, Paul M. A role for endothelin in the pathogenesis of hypertension: fact or fiction? Kidney Int Suppl 1998; 67: S115-21.
82. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47.
83. El-Gamal D, Holzer M, Gauster M, et al. Cyanate is a novel inducer of endothelial icam-1 expression. Antioxid Redox Signal 2012; 16: 129-37.
84. Larsson PT, Hallerstam S, Rosfors S, Wallen NH. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol 2005; 24: 43-51.
85. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-7.
86. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 2000; 36: 1210-6.
87. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15: 1624-30.
88. de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000; 36: 423-6.
89. Luc G, Arveiler D, Evans A, et al. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 2003; 170: 169-76.
90. Caliskan M, Erdogan D, Gullu H, et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008; 196: 306-12.
91. Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008; 75: 548-53.
92. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-53.
93. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
94. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007; 194: 46-54.
95. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
96. Distler JH, Beyer C, Schett G, Luscher TF, Gay S, Distler O. Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. Arthritis Rheum 2009; 60: 3168-79.
97. Lee PY, Li Y, Richards HB, Chan FS, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3759-69.
98. Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 865-70.
99. Molenaar TJ, Twisk J, de Haas SA, et al. P-selectin as a candidate target in atherosclerosis. Biochem Pharmacol 2003; 66: 859-66.
100. Schmitt-Sody M, Metz P, Gottschalk O, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 2007; 18: 365-72.
101. Schmitt-Sody M, Metz P, Klose A, et al. In vivo interactions of platelets and leucocytes with the endothelium in murine antigeninduced arthritis: the role of P-selectin. Scand J Rheumatol 2007; 36: 311-9.
102. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and Pselectin) in rheumatoid arthritis. Br J Rheumatol 1997; 36: 164-9.
103. Bhatia GS, Sosin MD, Patel JV, et al. Plasma indices of endothelial and platelet activation in Rheumatoid Disease: relationship to cardiovascular co-morbidity. Int J Cardiol 2009; 134: 97-103.
104. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, et al. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8: 437-49.
105. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006; 83: 447S-455S.
106. Shemesh S, Kamari Y, Shaish A, et al. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice. Atherosclerosis 2011.
107. Loppnow H, Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res 1989; 8: 293-9.
108. Wang X, Feuerstein GZ, Clark RK, Yue TL. Enhanced leucocyte adhesion to interleukin-1 beta stimulated vascular smooth muscle cells is mainly through intercellular adhesion molecule-1. Cardiovasc Res 1994; 28: 1808-14.
109. Clarke MC, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 2010; 106: 363-72.
110. Rechcinski T, Grebowska A, Kurpesa M, Sztybrych M, Peruga JZ, Trzos E, Rudnicka W, Krzeminska-Pakula M, Chmiela M. Interleukin-1b and interleukin-1 receptor inhibitor gene cluster polymorphisms in patients with coronary artery disease after percutaneous angioplasty or coronary artery bypass grafting. Kardiol Pol 2009; 67: 601-10.
111. Chamberlain J, Francis S, Brookes Z, et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 2009; 4: e5073.
112. Luotola K, Pietila A, Alanne M, et al. Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes. Metabolism 2010; 59: 1520-7.
113. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 27-55.
114. Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 2008; 117: 2577-9.
115. Cartier A, Bergeron J, Poirier P, et al. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann Med 2009; 41: 471-8.
116. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89: 372-6.
117. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-70.
118. Lee YW, Hirani AA. Role of interleukin-4 in atherosclerosis. Arch Pharm Res 2006; 29: 1-15.
119. Lee YW, Lee WH, Kim PH. Oxidative mechanisms of IL-4-induced IL-6 expression in vascular endothelium. Cytokine 2010; 49: 73-9.
120. Lee YW, Lee WH, Kim PH. Role of NADPH oxidase in interleukin-4-induced monocyte chemoattractant protein-1 expression in vascular endothelium. Inflamm Res 2010; 59: 755-65.
121. Walch L, Massade L, Dufilho M, Brunet A, Rendu F. Proatherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 2006; 187: 285-91.
122. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm 2009; 80: 613-33.
123. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26.
124. Abeywardena MY, Leifert WR, Warnes KE, Varghese JN, Head RJ. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009; 15: 1809-21.
125. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003; 92: 522-8.
126. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007; 13: 719-24.
127. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 2002; 1: 111-7.
128. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized lowdensity lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002; 252: 440-7.
129. Addabbo F, Mallamaci F, Leonardis D, et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 2007; 22: 3521-6.
130. Niu W, Liu Y, Qi Y, Wu Z, Zhu D, Jin W. Association of interleukin-6 circulating levels with coronary artery disease: A meta-analysis implementing mendelian randomization approach. Int J Cardiol 2012.
131. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008; 5: e78.
132. Karakas M, Baumert J, Greven S, Ruckerl R, Peters A, Koenig W. Reproducibility in serial C-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: results from the AIRGENE study. Clin Chem 2010; 56: 861-4.
133. Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001; 159: 137-44.
134. Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al. Antiinflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. Int J Cardiol 2003; 92: 169-75.
135. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
136. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-6.
137. Welsh P, Murray HM, Ford I, et al. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol 2011; 31: 2338-44.
138. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-9.
139. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-14.
140. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31: 2080-9.
141. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117: 1538-49.
142. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8: 22.
143. Choi YS, Choi HJ, Min JK, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114: 3117-26.
144. Kuchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008; 173: 1229-42.
145. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007; 40: 216-25.
146. Miller AM, Liew FY. The IL-33/ST2 pathway-A new therapeutic target in cardiovascular disease. Pharmacol Ther 2011; 131: 179-86.
147. Zhu J, Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine 2012.
148. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339-46.
149. Abston ED, Barin JG, Cihakova D, et al. IL-33 Independently Induces Eosinophilic Pericarditis and Cardiac Dilation: ST2 Improves Cardiac Function. Circ Heart Fail 2012.
150. Laman JD, de Smet BJ, Schoneveld A, van Meurs M. CD40-CD40L interactions in atherosclerosis. Immunol Today 1997; 18: 272-7.
151. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002; 12: 27-32.
152. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med 2011; 43: 331-40.
153. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm 2010; 2010: 174341.
154. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble Pselectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109: 2524-8.
155. Ludewig B, Henn V, Schroder JM, Graf D, Kroczek RA. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol 1996; 26: 3137-43.
156. Blake GJ, Ostfeld RJ, Yucel EK, et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003; 23: e11-4.
157. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
158. Yuan M, Ohishi M, Wang L, et al. Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patients. Clin Exp Pharmacol Physiol 2010; 37: 848-51.
159. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
160. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
161. Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the-3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1667-73.
162. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-77.
163. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997; 59: 63-88.
164. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-83.
165. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007; 21: 3029-41.
166. de Nooijer R, Bot I, von der Thusen JH, et al. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 188-94.
167. Gu FF, Lu SZ, Chen YD, et al. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J (Engl) 2009; 122: 2820-6.
168. Jobs E, Riserus U, Ingelsson E, et al. Serum cathepsin S is associated with serum C-reactive protein and interleukin-6 independently of obesity in elderly men. J Clin Endocrinol Metab 2010; 95: 4460-4.
169. Taleb S, Cancello R, Poitou C, et al. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. J Clin Endocrinol Metab 2006; 91: 1042-7.
170. Liu J, Ma L, Yang J, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006; 186: 411-9.
171. Chae JS, Kim OY, Paik JK, et al. Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome. Atherosclerosis 2011; 218: 499-506.
172. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-42.
173. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-3.
174. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101: 41F-50F.
175. Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006; 37: 1407-12.
176. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am J Cardiol 2006; 98: 9P-17P.
177. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000; 28: 1717-25.
178. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23: 447-54.
179. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 2009; 55: 1462-70.
180. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 50: 159-65.
181. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-42.
182. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-604.
183. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110: 1134-9.
184. Matijevic N, Wu KK, Nidkarni N, Heiss G, Folsom AR. The ARIC carotid MRI study of blood cellular markers: an inverse association of monocyte myeloperoxidase content with peripheral arterial disease. Angiology 2011; 62: 237-44.
185. Chen LQ, Rohatgi A, Ayers CR, et al. Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study. Atherosclerosis 2011; 219: 833-8.
186. Haslacher H, Perkmann T, Gruenewald J, et al. Plasma myeloperoxidase level and peripheral arterial disease. Eur J Clin Invest 2011.
187. Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med 2012; 271: 43-50.
188. Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis 2010; 21: 129-36.
189. Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009; 2: 1093-9.
190. Tomita T, Nakamura K. Isolation and identification of NGmonomethyl-, NG, NG-dimethylarginine and Nepsilontrimethyllysine from human placenta[1]. Hoppe Seylers Z Physiol Chem 1977; 358: 413-6.
191. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37: 2024-9.
192. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-7.
193. Mihout F, Shweke N, Bige N, et al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol 2011; 223: 37-45.
194. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493 e1-8.
195. Tsioufis C, Dimitriadis K, Andrikou E, et al. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. Am J Kidney Dis 2010; 55: 1050-9.
196. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011; 153: 135-40.
197. Bergheanu SC, van der Laarse A, van der Bom JG, et al. Asymmetric dimethylarginine (ADMA) levels display a morning peak in patients with acute myocardial infarction. Dis Markers 2011; 30: 245-52.
198. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008; 28: 961-7.
199. Szuba A, Podgorski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor-evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006; 58 Suppl: 16-20.
200. Wanby P, Teerlink T, Brudin L, et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006; 185: 271-7.
201. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007; 56: 809-19.
202. Turiel M, Atzeni F, Tomasoni L, et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 2009; 48: 834-9.
203. Atzeni F, Sarzi-Puttini P, Sitia S, et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2011; 38: 1661-4.
204. Sari I, Kebapcilar L, Alacacioglu A, et al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med 2009; 48: 1363-8.
205. Kemeny-Beke A, Gesztelyi R, Bodnar N, et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine 2011; 78: 184-7.
206. Lee DH, Blomhoff R, Jacobs DR, Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004; 38: 535-9.
207. Teschke R, Brand A, Strohmeyer G. Induction of hepatic microsomal gamma-glutamyltransferase activity following chronic alcohol consumption. Biochem Biophys Res Commun 1977; 75: 718-24.
208. Turgut O, Yilmaz A, Yalta K, Karadas F, Birhan Yilmaz M. γ-Glutamyltransferase is a promising biomarker for cardiovascular risk. Med Hypotheses 2006; 67: 1060-4.
209. Paolicchi A, Minotti G, Tonarelli P, et al. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation-a potential mechanism in atherosclerosis. J Investig Med 1999; 47: 151-60.
210. Arnesen E, Huseby NE, Brenn T, Try K. The Tromso Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest 1986; 46: 63-70.
211. Betro MG, Oon RC, Edwards JB. Gamma-glutamyl transpeptidase and other liver function tests in myocardial infarction and heart failure. Am J Clin Pathol 1973; 60: 679-83.
212. Nystrom E, Bengtsson C, Lindstedt G, et al. Serum gammaglutamyltransferase in a Swedish female population. Age-related reference intervals; morbidity and prognosis in cases with raised catalytic concentration. Acta Med Scand 1988; 224: 79-84.
213. van Barneveld T, Seidell JC, Traag N, Hautvast JG. Fat distribution and gamma-glutamyl transferase in relation to serum lipids and blood pressure in 38-year old Dutch males. Eur J Clin Nutr 1989; 43: 809-18.
214. Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Yamaya H. Relationship between serum gamma-glutamyl transpeptidase activity and blood pressure in middle-aged male and female nondrinkers. J Hum Hypertens 1990; 4: 609-14.
215. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112: 2130-7.
216. Lee DH, Silventoinen K, Hu G, et al. Serum gammaglutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006; 27: 2170-6.
217. Schutte R, Schutte AE, Huisman HW, et al. Blood glutathione and subclinical atherosclerosis in African men: the SABPA Study. Am J Hypertens 2009; 22: 1154-9.
218. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middleaged men from the general population. Circulation 2005; 112: 651-7.
219. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002; 22: 1649-54.
220. Rietzschel ER, Langlois M, De Buyzere ML, et al. Oxidized lowdensity lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension 2008; 52: 535-41.
221. Kotani K, Caccavello R, Taniguchi N, Gugliucci A. Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects. J Int Med Res 2012; 40: 1878-83.
222. Verhoye E, Langlois MR. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med 2009; 47: 128-37.
223. Holvoet P, Harris TB, Tracy RP, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003; 23: 1444-8.
224. Koenig W, Karakas M, Zierer A, et al. Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem 2011; 57: 1196-200.
225. Draper HH, Hadley M. A review of recent studies on the metabolism of exogenous and endogenous malondialdehyde. Xenobiotica 1990; 20: 901-7.
226. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-82.
227. Tsimikas S, Palinski W, Witztum JL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 95-100.
228. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95: 2611-9.
229. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 2002; 22: 662-6.
230. Viigimaa M, Abina J, Zemtsovskaya G, et al. Malondialdehydemodified low-density lipoproteins as biomarker for atherosclerosis. Blood Press 2010; 19: 164-8.
231. Wang J, Hu B, Meng Y, Zhang C, Li K, Hui C. The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis. Clin Biochem 2009; 42: 1352-7.
232. Djuric D, Wisotzki R, Mitrovic V. Homocysteine and arteriosclerosis: established risk factor or new illusion? Am J Ther 2000; 7: 381-7.
233. Tehlivets O. Homocysteine as a risk factor for atherosclerosis: is its conversion to s-adenosyl-L-homocysteine the key to deregulated lipid metabolism? J Lipids 2011; 2011: 702853.
234. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.
235. Vizzardi E, Nodari S, Fiorina C, Metra M, Dei Cas L. Plasma homocysteine levels and late outcome in patients with unstable angina. Cardiology 2007; 107: 354-9.
236. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
237. Turhan H, Aksoy Y, Yetkin E. Homocysteine and coronary microcirculation: is it a microvasculopathic agent? Int J Cardiol 2006; 110: 269-70.
238. Wei JC, Jan MS, Yu CT, et al. Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 739-42.
239. Katayama T, Nakashima H, Takagi C, et al. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ J 2005; 69: 1186-91.